BRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Reuters

22 Apr

BRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential

April 22 (Reuters) - MetaVia Inc MTVA.O:

METAVIA REPORTS ADDITIONAL POSITIVE TOP-LINE RESULTS FROM THE MAD PART 2 OF ITS PHASE 1 STUDY OF DA-1726, A NOVEL 3:1 RATIO GLP-1 AND GLUCAGON DUAL RECEPTOR AGONIST TO TREAT OBESITY, FURTHER DEMONSTRATING ITS BEST-IN-CLASS POTENTIAL
METAVIA INC: A DOSE-DEPENDENT RESPONSE IN BODY WEIGHT REDUCTION WAS OBSERVED BETWEEN 8 MG AND 32 MG DOSES
METAVIA INC: CHANGE IN BMI AND BODY WEIGHT ADJUSTED FOR HEIGHT IN TREATMENT GROUPS, SHOWED A SIGNIFICANT DIFFERENCE COMPARED TO PLACEBO
METAVIA: NO DRUG-INDUCED CARDIOVASCULAR EFFECTS OBSERVED IN HEART RATE/QTCF MEASUREMENTS OF SUBJECTS GETTING UP TO 32 MG OF DA-1726 AT 4-WEEKS
METAVIA INC: ADDITIONAL COHORTS BEING ADDED TO DETERMINE MAXIMUM TOLERATED DOSE

Source text: ID:nPn48yhCwa

Further company coverage: MTVA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2529301664"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2529301664\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2529301664?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-22 20:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529301664","market":"nz","top_or_hot":-1,"title":"BRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential</title></head><body><p><span>April 22 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/MTVA\">MetaVia Inc</a> <span>MTVA.O</span>:</p><ul><li><p>METAVIA REPORTS ADDITIONAL POSITIVE TOP-LINE RESULTS FROM THE MAD PART 2 OF ITS PHASE 1 STUDY OF DA-1726, A NOVEL 3:1 RATIO GLP-1 AND GLUCAGON DUAL RECEPTOR AGONIST TO TREAT OBESITY, FURTHER DEMONSTRATING ITS BEST-IN-CLASS POTENTIAL</p></li><li><p>METAVIA INC: A DOSE-DEPENDENT RESPONSE IN BODY WEIGHT REDUCTION WAS OBSERVED BETWEEN 8 MG AND 32 MG DOSES</p></li><li><p>METAVIA INC: CHANGE IN BMI AND BODY WEIGHT ADJUSTED FOR HEIGHT IN TREATMENT GROUPS, SHOWED A SIGNIFICANT DIFFERENCE COMPARED TO PLACEBO</p></li><li><p>METAVIA: NO DRUG-INDUCED CARDIOVASCULAR EFFECTS OBSERVED IN HEART RATE/QTCF MEASUREMENTS OF SUBJECTS GETTING UP TO 32 MG OF DA-1726 AT 4-WEEKS</p></li><li><p>METAVIA INC: ADDITIONAL COHORTS BEING ADDED TO DETERMINE MAXIMUM TOLERATED DOSE</p></li></ul><p>Source text: <span>ID:nPn48yhCwa</span></p><p>Further company coverage: <span>MTVA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-22 20:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential</title></head><body><p><span>April 22 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/MTVA\">MetaVia Inc</a> <span>MTVA.O</span>:</p><ul><li><p>METAVIA REPORTS ADDITIONAL POSITIVE TOP-LINE RESULTS FROM THE MAD PART 2 OF ITS PHASE 1 STUDY OF DA-1726, A NOVEL 3:1 RATIO GLP-1 AND GLUCAGON DUAL RECEPTOR AGONIST TO TREAT OBESITY, FURTHER DEMONSTRATING ITS BEST-IN-CLASS POTENTIAL</p></li><li><p>METAVIA INC: A DOSE-DEPENDENT RESPONSE IN BODY WEIGHT REDUCTION WAS OBSERVED BETWEEN 8 MG AND 32 MG DOSES</p></li><li><p>METAVIA INC: CHANGE IN BMI AND BODY WEIGHT ADJUSTED FOR HEIGHT IN TREATMENT GROUPS, SHOWED A SIGNIFICANT DIFFERENCE COMPARED TO PLACEBO</p></li><li><p>METAVIA: NO DRUG-INDUCED CARDIOVASCULAR EFFECTS OBSERVED IN HEART RATE/QTCF MEASUREMENTS OF SUBJECTS GETTING UP TO 32 MG OF DA-1726 AT 4-WEEKS</p></li><li><p>METAVIA INC: ADDITIONAL COHORTS BEING ADDED TO DETERMINE MAXIMUM TOLERATED DOSE</p></li></ul><p>Source text: <span>ID:nPn48yhCwa</span></p><p>Further company coverage: <span>MTVA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MTVA","symbol_name":"MetaVia Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA6ZJ01N:1","article_id":"2529301664","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529301664","pubTimestamp":1745325188,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demo","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"MTVA":"MetaVia Inc"},"translate_title":"简介-MetaVia报告了DA-1726 1期研究Mad第2部分的额外积极顶线结果，Da-1726是一种用于治疗肥胖症的新型31比率Glp-1和胰高血糖素双重受体激动剂，进一步证明了其同类最佳的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MTVA":0.9},"content_text":"BRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class PotentialApril 22 (Reuters) - MetaVia Inc MTVA.O:METAVIA REPORTS ADDITIONAL POSITIVE TOP-LINE RESULTS FROM THE MAD PART 2 OF ITS PHASE 1 STUDY OF DA-1726, A NOVEL 3:1 RATIO GLP-1 AND GLUCAGON DUAL RECEPTOR AGONIST TO TREAT OBESITY, FURTHER DEMONSTRATING ITS BEST-IN-CLASS POTENTIALMETAVIA INC: A DOSE-DEPENDENT RESPONSE IN BODY WEIGHT REDUCTION WAS OBSERVED BETWEEN 8 MG AND 32 MG DOSESMETAVIA INC: CHANGE IN BMI AND BODY WEIGHT ADJUSTED FOR HEIGHT IN TREATMENT GROUPS, SHOWED A SIGNIFICANT DIFFERENCE COMPARED TO PLACEBOMETAVIA: NO DRUG-INDUCED CARDIOVASCULAR EFFECTS OBSERVED IN HEART RATE/QTCF MEASUREMENTS OF SUBJECTS GETTING UP TO 32 MG OF DA-1726 AT 4-WEEKSMETAVIA INC: ADDITIONAL COHORTS BEING ADDED TO DETERMINE MAXIMUM TOLERATED DOSESource text: ID:nPn48yhCwaFurther company coverage: MTVA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}